Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lithium carbonate, quantity: 250 mg - tablet, film coated - excipient ingredients: dextrin; lactose monohydrate; macrogol 6000; sodium starch glycollate type a; purified talc; sodium lauryl sulfate; magnesium stearate; hypromellose; maize starch - mania, both as treatment and prophylaxis; manic depressive (bipolar) illness, both as treatment and as prophylaxis; it is less effective in depressive swings. in recurrent endogenous (unipolar) depressive illness, it is highly effective as prophylaxis in a number of cases, and is probably useful as treatment, especially if there is a family history of manic depressive illness and response to lithium. in some cases of schizoaffective illness and so called chronic schizophrenia it is dramatically effective. those in the latter category who do respond have frequently had affective symptoms at some time. it is used in character or personality disorders in young people with clear evidence of cyclothymia. lithium should not be prescribed until it is certain that the manic depressive swings are established and the course of the disease certain. if the patient has two affective swings in one year, perhaps in opposite directions, and associated with a positive family history, it should certainly be seriously considered. with three episodes in two years, there is no doubt it should be given. as a general rule, it should be prescribed, and therapeutic response assessed, satisfactory maintenance dosage determined, side and toxic effects and associated precautions discussed with the patient and relatives, and blood levels monitored, only under specialist supervision except perhaps in isolated areas. a major management problem also is that there are relatively narrow distances between the therapeutic and toxic dosages and blood levels. for these reasons treatment is preferably commenced on an inpatient basis, so that the patient is under appropriate observation.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

saja-saudi arabian japanese pharmaceutical co - ritodrine - tablet - 10 mg

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - nefazodone hydrochloride (unii: 27x63j94gr) (nefazodone - unii:59h4fcv1tf) - tablet - 50 mg - nefazodone hydrochloride tablets, usp is indicated for the treatment of depression. when deciding among the alternative treatments available for this condition, the prescriber should consider the risk of hepatic failure associated with nefazodone hydrochloride tablets, usp treatment (see warnings ). in many cases, this would lead to the conclusion that other drugs should be tried first. the efficacy of nefazodone in the treatment of depression was established in 6 to 8 week controlled trials of outpatients and in a 6-week controlled trial of depressed inpatients whose diagnoses corresponded most closely to the dsm-iii or dsm-iiir category of major depressive disorder (see clinical pharmacology ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks). it must include either depressed mood or loss of interest or pleasure and at least five of the following nine symptoms: depressed

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

durbin plc - ritodrine hydrochloride - oral tablet - 10mg

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; purified talc; pregelatinised maize starch; microcrystalline cellulose; sodium lauryl sulfate; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; indigo carmine aluminium lake; quinoline yellow aluminium lake; macrogol 400 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment (up to 12 weeks) of psychotic symptoms, or persistent agitations or aggression unresponsive to non-pharmacological approaches, in patients with moderate to severe dementia of the alzheimer type. treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see 5.1 pharmacodynamic properties, clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see 5.1 pharmacodynamic properties, clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; pregelatinised maize starch; purified talc; lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; quinoline yellow aluminium lake; macrogol 400 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment (up to 12 weeks) of psychotic symptoms, or persistent agitations or aggression unresponsive to non-pharmacological approaches, in patients with moderate to severe dementia of the alzheimer type. treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see 5.1 pharmacodynamic properties, clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see 5.1 pharmacodynamic properties, clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; sodium lauryl sulfate; purified talc; microcrystalline cellulose; pregelatinised maize starch; lactose monohydrate; titanium dioxide; hypromellose; sunset yellow fcf aluminium lake; quinoline yellow aluminium lake; macrogol 400 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment (up to 12 weeks) of psychotic symptoms, or persistent agitations or aggression unresponsive to non-pharmacological approaches, in patients with moderate to severe dementia of the alzheimer type. treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see 5.1 pharmacodynamic properties, clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see 5.1 pharmacodynamic properties, clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; microcrystalline cellulose; purified talc; sodium lauryl sulfate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment (up to 12 weeks) of psychotic symptoms, or persistent agitations or aggression unresponsive to non-pharmacological approaches, in patients with moderate to severe dementia of the alzheimer type. treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see 5.1 pharmacodynamic properties, clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see 5.1 pharmacodynamic properties, clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - risperidone, quantity: 0.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate; colloidal anhydrous silica; pregelatinised maize starch; sodium lauryl sulfate; purified talc; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment (up to 12 weeks) of psychotic symptoms, or persistent agitations or aggression unresponsive to non-pharmacological approaches, in patients with moderate to severe dementia of the alzheimer type. treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see 5.1 pharmacodynamic properties, clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see 5.1 pharmacodynamic properties, clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 28.78 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: silicon dioxide; sodium starch glycollate type a; iron oxide yellow; povidone; lactose monohydrate; microcrystalline cellulose; iron oxide red; calcium hydrogen phosphate dihydrate; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - quetiapine sandoz is indicated for:,bipolar disorder adults ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dose and method of administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years ? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years) ? treatment of schizophrenia